• 1
    Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997;24:44551.
  • 2
    Gabriel SE, Crowson CS, O'Fallon WM. Comorbidity in arthritis. J Rheumatol 1999;26:24759.
  • 3
    Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:273745.
  • 4
    Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD. Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 2002;1:33847.
  • 5
    Stevens RJ, Douglas KM, Saratzis AN, Kitas GD. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med 2005;7:124.
  • 6
    Nurmohamed MT, Kitas G. Cardiovascular risk in rheumatoid arthritis and diabetes: how does it compare and when does it start?Ann Rheum Dis 2011;70:8813.
  • 7
    Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:32531.
  • 8
    Cruz W, Fialho S, Morato E, Castro G, Zimmermann A, Ribeiro G, et al. Is there a link between inflammation and abnormal lipoprotein profile in Sjögren's syndrome?Joint Bone Spine 2010;77:22931.
  • 9
    Perez-De-Lis M, Akasbi M, Siso A, Diez-Cascon P, Brito-Zeron P, Diaz-Lagares C, et al. Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients. Lupus 2010;19:9418.
  • 10
    Rachapalli SM, Kiely PD, Bourke BE. Prevalence of abnormal ankle brachial index in patients with primary Sjögren's syndrome. Clin Rheumatol 2009;28:58790.
  • 11
    Vaudo G, Bocci EB, Shoenfeld Y, Schillaci G, Wu R, Del PN, et al. Precocious intima-media thickening in patients with primary Sjögren's syndrome. Arthritis Rheum 2005;52:38907.
  • 12
    Lodde BM, Sankar V, Kok MR, Leakan RA, Tak PP, Pillemer SR. Serum lipid levels in Sjögren's syndrome. Rheumatology (Oxford) 2006;45:4814.
  • 13
    Ng WF, Bowman SJ, Griffiths B. United Kingdom Primary Sjögren's Syndrome Registry: a united effort to tackle an orphan rheumatic disease. Rheumatology (Oxford) 2011;50:329.
  • 14
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:5548.
  • 15
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:53953.
  • 16
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive summary of the third report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA 2001;285:248697.
  • 17
    National Institute for Health and Clinical Excellence. Hypertension. Clinical management of primary hypertension in adults.2013. URL:
  • 18
    Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994;7:7S12S.
  • 19
    Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?Arthritis Rheum 2002;46:86273.
  • 20
    Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005;112:333747.
  • 21
    Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399406.
  • 22
    Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007;46:147782.
  • 23
    Panoulas VF, Douglas KM, Smith JP, Taffe P, Stavropoulos-Kalinoglou A, Toms TE, et al. Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis. Endothelium 2008;15:20312.
  • 24
    Panoulas VF, Douglas KM, Smith JP, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, et al. Transforming growth factor-β1 869T/C, but not interleukin-6 -174G/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2009;48:1138.
  • 25
    Toms TE, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol 2010;8:30126.
  • 26
    Pearson TA, Mensah GA, Hong Y, Smith SC Jr.CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: overview. Circulation 2004;110:e5434.
  • 27
    De Oliveira C, Watt R, Hamer M. Toothbrushing, inflammation, and risk of cardiovascular disease: results from Scottish Health Survey. BMJ 2010;340:c2451.
  • 28
    Fedele S, Sabbah W, Donos N, Porter S, D'Aiuto F. Common oral mucosal diseases, systemic inflammation, and cardiovascular diseases in a large cross-sectional US survey. Am Heart J 2011;161:34450.
  • 29
    Li CY, Sung FC. A review of the healthy worker effect in occupational epidemiology. Occup Med (Lond) 1999;49:2259.
  • 30
    Desai SS, Myles JD, Kaplan MJ. Suboptimal cardiovascular risk factor identification and management in patients with rheumatoid arthritis: a cohort analysis. Arthritis Res Ther 2012;14:R270.
  • 31
    Elliott JR, Manzi S. Cardiovascular risk assessment and treatment in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2009;23:48194.